As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.
Study identifier: NCT01477489
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Breast cancer with either
a) locoregional recurrence after previous mastectomy or,
b) inflammatory breast cancer status post mastectomy for which radiotherapy to the chest wall and regional nodes is planned as part of treatment.
Patients with Stage IV disease are eligible as long as they meet these criteria.
Type of study:
Phase I study
Veliparib twice daily and standard radiation treatment
New York City
Memorial Sloan Ketter Cancer Center
Contact: Dr. Beryl McCormick: 212-639-6756 email@example.com